Changeflow GovPing Healthcare & Life Sciences Novel Compounds Promote Hair Growth and Inflamm...
Routine Notice Added Draft

Novel Compounds Promote Hair Growth and Inflammatory Disorder Inhibition

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

Chang Gung University of Science and Technology has published patent application US20260109682A1, filed October 20, 2024, covering novel compounds with structures of formula (I), (II), or (III) for promoting hair growth or inhibiting inflammatory disorders including acute respiratory distress syndrome and acute liver injury. The compounds or their pharmaceutically acceptable salts may be used to manufacture pharmaceutical compositions for the stated therapeutic indications. This A1 publication makes the application publicly available; patent prosecution and any resulting grant remain pending.

“Novel compounds and their use for promoting hair growth or inhibiting inflammatory disorders thereof are provided, the compounds have a structure of a formula (I) or a formula (II) or a formula (III), and the compounds or their pharmaceutically acceptable salts can be used for the manufacture of pharmaceutical composition for promoting hair growth or inhibiting inflammatory disorders, the inflammatory disorders including acute respiratory distress syndrome or acute liver injury.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 223 changes logged to date.

What changed

Chang Gung University of Science and Technology has published patent application US20260109682A1, covering novel compounds and their pharmaceutical compositions for promoting hair growth or inhibiting inflammatory disorders. The application identifies specific compound structures (formula I, II, and III) and lists therapeutic applications including acute respiratory distress syndrome and acute liver injury.

Pharmaceutical companies and drug manufacturers should monitor this application as it may indicate competitive activity in the dermatology and anti-inflammatory therapeutic spaces. Parties developing hair-growth therapeutics or anti-inflammatory drugs should review the claimed compound structures and therapeutic indications for potential overlap with their own pipeline assets. This publication does not represent a granted patent and imposes no immediate compliance obligations.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

NOVEL COMPOUNDS AND THE USE FOR PROMOTING HAIR GROWTH OR INHIBITING INFLAMMATORY DISORDERS THEREOF

Application US20260109682A1 Kind: A1 Apr 23, 2026

Assignee

Chang Gung University of Science and Technology

Inventors

Tsong-Long Hwang, Hsun-Shuo Chang, Chia-Hung Yen, Yu-Chun Lin, Tzu-Peng Cheng, Ya-Lun Chen, Ching-Ju Yang

Abstract

Novel compounds and their use for promoting hair growth or inhibiting inflammatory disorders thereof are provided, the compounds have a structure of a formula (I) or a formula (II) or a formula (III), and the compounds or their pharmaceutically acceptable salts can be used for the manufacture of pharmaceutical composition for promoting hair growth or inhibiting inflammatory disorders, the inflammatory disorders including acute respiratory distress syndrome or acute liver injury.

CPC Classifications

C07D 311/96 A61K 31/352 A61K 36/61 A61P 11/00 A61P 17/14 C07D 311/74 C07D 401/00

Filing Date

2024-10-20

Application No.

18920975

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
October 20th, 2024
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260109682A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Drug formulation research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!